business insider retatrutide isn't supposed to be everywhere. Touted as the next generation in the GLP-1 craze, it's an experimental weight-loss drug that is not authorized outside of clinical trials. The Food and Drug I'm Worried! Triple Agonist GLP-1

Current research on the relative benefits and safety of non-FDA approved alternatives compared to the more expensive agents may help improve access to GLP-1 agonists.

Easier access: With availability at tens of thousands of U.S

The cardiovascular phenomenon of endothelial dysfunction involves a series of structural and functional abnormalities, including abnormal secretory capacity and properties of the endothelium and impaired vascular tone, as well as an impaired endothelial barrier function

That is the main cardiovascular signal researchers are watching closely

Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: A double-blind, randomised, placebo-controlled, phase 4 clinical trial

It is currently under clinical investigation and has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)